RxDoctor Payments Data

Amy Emerick

Psychiatric/Mental Health · Cookeville, TNNPI 1003400870

Payments from drug & device makers

$4,763in general payments, 2019–2025

Across 265 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$852
  • Teva Pharmaceuticals USA, Inc.$611
  • Johnson & Johnson$351
  • Neurocrine Biosciences, Inc.$346
  • Corium, LLC$345
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,71699%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,763 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$90,478
Medicare patients
134
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$163,868
SpravatoEsketamine Hcl59$131,528
Austedo XrDeutetrabenazine19$95,427
RexultiBrexpiprazole27$38,988
VraylarCariprazine Hcl26$28,093
BelsomraSuvorexant16$6,582
TrintellixVortioxetine Hydrobromide13$6,238
Divalproex Sodium60$2,774
Trazodone Hcl186$1,599
Quetiapine Fumarate153$1,557
Bupropion XlBupropion Hcl42$1,431
Chlorpromazine Hcl11$1,298
Duloxetine Hcl71$1,290
Mirtazapine76$1,172
Olanzapine41$1,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$346$163,86813 claims
Johnson & JohnsonSpravato$351$131,52859 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$611$95,42719 claims
Otsuka America Pharmaceutical, Inc.Rexulti$138$38,98827 claims
AbbVieVraylar$1,027$28,09326 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$6,23813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →